The Phase 3 trial enrolled 251 patients aged 12-17 years old with moderate-to-severe atopic dermatitis, whose disease was not adequately controlled by prescription topical medications or for whom topical treatment was medically inadvisable.
The Phase 3 study (N=318) enrolled patients aged 18 to 78 years with moderate-to-severe chronic plaque psoriasis who had not previously received treatment with ≥1 biologic.
Preliminary results from a Phase 1b proof-of-concept study showed that SYNT001 was associated with clinical improvement (as measured by Pemphigus Disease Area Index score) and induced a rapid reduction in lgG and circulating immune complex levels.
To investigate the effectiveness of CAM modalities in the treatment of plaque psoriasis, researchers searched several databases to identify studies where CAM was used as an intervention.
The case involved a 55-year-old female patient who had been admitted to the hospital after suffering injuries from a car accident.
PF-06651600 is an investigational oral Janus kinase 3 (JAK3) inhibitor that is being evaluated in a Phase 2 study which will assess the treatment based on changes from baseline in Severity of Alopecia Tool (SALT) score.
Its long-term safety was evaluated in a phase 3, multicenter, open-label study of 555 adults with moderate to severe plaque psoriasis.
The Company is seeking approval for the treatment to temporarily improve the appearance of moderate to severe glabellar lines.
Systemic therapy treatment chart for psoriasis patients generally reserved for those with chronic plaque psoriasis without psoriatic arthritis who are candidates for systemic treatment when UV therapy is not available.
The approval was based on 2 double-blind clinical trials involving 1640 patients 9 years of age and older with moderate to severe acne vulgaris.
Clinical data has indicated that the drug exhibits a low propensity for resistance development as well as a favorable tolerability profile.
Patients with TGM-1 deficiency may have chronic pronounced scaling of the skin with increased transepidermal water loss, as the TGM-1 enzyme is essential for facilitating the formation of the epidermal barrier, which prevents dehydration.
The Committee's recommendation was based on data from the omadacycline global development program that included nearly 2000 adults in three Phase 3 studies.
"If these findings are confirmed, adherence to a Mediterranean diet should be integrated into the routine management of moderate to severe psoriasis," the authors write.
Lice and scabies treatment chart, including pediculicides, scabicides, and lice and nit removal aids.
"In the case of BBQ fumes, dermal absorption was a more important pathway for intake of low-molecular-weight PAHs than inhalation," the authors write.
Wound care dressings and cleansers including hydrocolloid occlusive dressings, wet-to-dry dressings, hydrogels, foam dressings, odor-controlling dressings, and xerogels.
Adults with AD reported higher proportions of having only fair/poor overall health, being somewhat/very dissatisfied with life, having lower weighted mean Short-Form 12 (SF-12) mental and physical health subscores, and having higher Dermatology Life Quality Index scores, compared to adults without AD.
The approval was supported by Phase 3 data from the ATMOS-1 and ATMOS-2 trials which evaluated the absolute change from baseline in sweat production after treatment with Qbrexza, and the proportion of patients who achieved ≥4-point improvement from baseline in their sweating severity (as measured by the Axillary Sweating Daily Diary [ASDD]).
The new rule allows pharmacists to prescribe medications for cold sores, seasonal influenza, strep throat, and urinary tract infections, as well as statins for patients with diabetes.
Oral medications for the treatment of acne including dosing for antibiotics, retinoids, and contraceptives.
A chart of topical acne medications for the use in children and adults including available strengths.
In a press release Dr. David Young, CEO of Processa said "We plan to begin our clinical studies in 2018 and to accelerate the development of PCS499 in order to provide clinical benefit to [necrobiosis lipoidica] patients as soon as possible."
The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."